| 1. |
中华医学会眼科学分会神经眼科学组. 视神经炎诊断和治疗专家共识(2014年)[J]. 中华眼科杂志, 2014(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.Neuro-ophthalmology Group, Ophthalmology Branch, Chinese Medical Association. Expert consensus on diagnosis and treatment of optic neuritis (2014)[J]. Chin J Ophthalmol, 2014(6): 459-463. DOI: 10.3760/cma.j.issn.0412-4081.2014.06.013.
|
| 2. |
Shi J, Danesh-Meyer HV, Bhatti MT. Neuroretinitis: a comprehensive review on aetiologies, clinical manifestations, and treatment options[J]. Eye (Lond), 2025, 39(2): 238-250. DOI: 10.1038/s41433-024-03466-7.
|
| 3. |
Fairbanks AM, Starr MR, Chen JJ, et al. Treatment strategies for neuroretinitis: Current options and emerging therapies[J/OL]. Curr Treat Options Neurol, 2019, 21(8): 36[2019-07-05]. https://pubmed.ncbi.nlm.nih.gov/31278547/. DOI: 10.1007/s11940-019-0579-9.
|
| 4. |
Abdelhakim A, Rasool N. Neuroretinitis: a review[J]. Curr Opin Ophthalmol, 2018, 29(6): 514-519. DOI: 10.1097/ICU.0000000000000527.
|
| 5. |
Uzawa A, Oertel FC, Mori M, et al. NMOSD and MOGAD: an evolving disease spectrum[J]. Nat Rev Neurol, 2024, 20(10): 602-619. DOI: 10.1038/s41582-024-01014-1.
|
| 6. |
Chan F, Fraser C, Brilot F, et al. Structural and functional biomarkers of visual dysfunction in MOG antibody-positive optic neuritis: a scoping review[J/OL]. J Neuroimmunol, 2025, 408: 578715[2028-11-15]. https://pubmed.ncbi.nlm.nih.gov/40829360/. DOI: 10.1016/j.jneuroim.2025.578715.
|
| 7. |
Nowacka B, Lubiński W, Kaźmierczak B. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated optic neuritis-a case report and literature review[J]. Int Med Case Rep J, 2024, 17: 391-399. DOI: 10.2147/IMCRJ.S459799.
|
| 8. |
Jeyakumar N, Lerch M, Dale RC, et al. MOG antibody-associated optic neuritis[J]. Eye, 2024, 38(12): 2289-2301. DOI: 10.1038/s41433-024-03108-y.
|
| 9. |
Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG-associated optic neuritis[J/OL]. Curr Neurol Neurosci Rep, 2019, 19(12): 100[2019-11-26]. https://pubmed.ncbi.nlm.nih.gov/31773369/. DOI: 10.1007/s11910-019-1014-z.
|
| 10. |
Galli M, Morelli R, Casellato A, et al. Retrobulbar optic neuritis in a patient with acute type B hepatitis[J]. J Neurol Sci, 1986, 72(2-3): 195-200. DOI: 10.1016/0022-510X(86)90007-9.
|
| 11. |
Achiron LR. Postinfectious hepatitis b optic neuritis[J]. Optometry vision sci, 1994, 71(1): 53-56. DOI: 10.1097/00006324-199401000-00011.
|
| 12. |
Curras-Martin D, Campbell N, Haroon A, et al. Recurrent optic neuritis as the only manifestation of chronic hepatitis b virus flare: a case report[J/OL]. J Med Case Rep, 2018, 12(1): 316[2018-10-16]. https://pubmed.ncbi.nlm.nih.gov/30326966/. DOI: 10.1186/s13256-018-1810-0.
|
| 13. |
Zhao S, Chen T, Peng C, et al. The putative acceleration of optic neuritis when combined with chronic hepatitis B[J]. J Neurol Sci, 2015, 358(1-2): 207-212. DOI: 10.1016/j.jns.2015.08.1538.
|
| 14. |
Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. the optic neuritis study group[J]. New Engl J Med, 1992, 326(9): 581-588. DOI: 10.1056/NEJM199202273260901.
|
| 15. |
Cacoub P, Terrier B. Hepatitis b-related autoimmune manifestations[J]. Rheum Dis Clin North Am, 2009, 35(1): 125-137. DOI: 10.1016/j.rdc.2009.03.006.
|
| 16. |
Hipolito-Fernandes D, Elisa-Luís M, Trigo M, et al. Parainfectious optic neuritis followed by microcystic macular oedema[J/OL]. BMJ Case Rep, 2019, 12(9): e231442[2019-09-24]. https://pubmed.ncbi.nlm.nih.gov/31551321/. DOI: 10.1136/bcr-2019-231442.
|
